Daniel Shevrin to Survival Rate
This is a "connection" page, showing publications Daniel Shevrin has written about Survival Rate.
Connection Strength
0.078
-
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. Urology. 2015 Dec; 86(6):1206-11.
Score: 0.022
-
5a-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol. 2015 Apr; 193(4):1388-93.
Score: 0.020
-
Phase II trial of echinomycin in advanced hormone-resistant prostate cancer. An Illinois Cancer Council study. Invest New Drugs. 1994; 12(1):65-6.
Score: 0.019
-
Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):221-6.
Score: 0.009
-
Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000 Aug; 23(4):371-5.
Score: 0.008